-
Published: July, 2024Source: 2024 JAMA Oncology
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma
-
Published: June, 2024Source: 2024 EHA Annual Meeting
A phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T AZD0120 (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
A phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T AZD0120 (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
-
Published: November, 2023Source: 2023 ASH Annual Meeting
Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
-
Published: November, 2023Source: 2023 SITC Annual Meeting
SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanced efficacy against solid tumors
Poster - SMART CAR-T cells resist tumor immunosuppressive microenvironment with enhanceo efficacy against solid tumors
-
Published: September, 2023Source: 2023 IMS Annual Meeting
Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
Phase I open-label single-arm study of dual targeting BCMA and CD19 FasTCAR-T cells (GC012F) as first-line therapy for transplant-eligible newly diagnosed high-risk multiple myeloma
-
Published: May, 2023Source: 2023 ASCO Annual Meeting, 2023 EHA Congress
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
Updated results of a phase I, open-label study of BCMA/CD19 dual-targeting fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
-
Published: May, 2023Source: 2023 ASCO Annual Meeting, 2023 EHA Congress
Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma
ASCO 2023 Poster - Updated Clinical Results of First-in-Human Study of CD19/BCMA Dual-Targeting FasT CAR-T GC012F for Patients with Relapsed/Refractory B-cell Non-Hodgkin’s Lymphoma
-
Published: May, 2023Source: 2023 EHA Congress
Donor-derived Anti-CD19 Chimeric Antigen Receptor T Cells for B-cell Acute Lymphoblastic Leukemia: a Phase 1 Trial
-
Published: November, 2022Source: 2022 ASH Annual Meeting Abstract
Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
Data Presentation - Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FastCAR-T GC012F as First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma
-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
EHA 2022 - Oral Presentation – Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
EHA 2022 - Poster - Early Results of a Safety and Efficacy Study of Allogeneic TruUCAR™ GC502 In Patients With Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL)
-
Published: June, 2022Source: 2022 EHA Annual Congress Abstract
First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
EHA 2022 - Poster –First-In-Human Study of CD19/BCMA Dual-Targeting FasTCAR-T GC012F For Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
-
Published: June, 2022Source: Journal of Clinical Oncology / 2022 ASCO Annual Meeting Abstract
Updated results of a multicenter first-in-human study of BCMA/CD19 dual-targeting FasTCAR-T GC012F for patients with relapsed/refractory multiple myeloma (RRMM)
-
Published: June, 2022Source: Cancer Research / 2022 AACR Annual Meeting Abstract
Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
AACR 2022 - Poster – Early results of a safety and efficacy study of allogeneic TruUCAR™ GC502 in patients with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
-
Published: November, 2021Source: Journal for Immuno Therapy of Cancer / 2021 SITC Annual Meeting Abstract
IL-2 Variant Improves CAR-T Functionality and Efficacy Against Solid Tumors
-
Published: November, 2021Source: Blood / 2021 ASH Annual Meeting Abstract
Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
ASH 2021 – Poster - Preclinical Results of an Allogeneic, Universal CD19/CD7-Targeting CAR-T Cell Therapy (GC502) for B Cell Malignancies
-
Published: August, 2021Source: Cellular & Molecular Immunology
Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors
-
Published: May, 2021Source: Journal of Clinical Oncology / 2021 ASCO Annual Meeting Abstract
Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted FasT CAR-T GC012F for patients with relapsed/refractory multiple myeloma
-
Published: April, 2021Source: 2021 AACR Annual Meeting Abstract
Updates on clinical safety and efficacy result of GC027, the first-in-human, “Off-the-Shelf” CD7 CAR-T stand-alone therapy for adult patients with relapsed/refractory T-cell lymphoblastic leukemia (r/r T-ALL)
-
Published: March, 2021Source: Clinical Cancer Research
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS Management
-
Published: December, 2020Source: 62nd ASH Annual Meeting, Oral Abstract
Successful 24-hours manufacture of anti-CD19/CD22 dual chimeric antigen receptor (CAR) T cell therapy for B-cell acute lymphoblastic leukemia (B-ALL)
-
Published: December, 2020Source: 62nd ASH Annual Meeting, Oral Abstract
Clinical results of a multicenter study of the first-in-human dual BCMA and CD19 targeted novel platform Fast CAR-T cell therapy for patients with relapsed/refractory multiple myeloma
-
Published: October, 2020Source: Leukemia
Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant
-
Published: April, 2020Source: 2020 AACR Annual Meeting Abstract
Clinical safety and efficacy study of TruUCAR™ GC027: The first-in-human, universal CAR-T therapy for adult relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL)
-
Published: July, 2019Source: Medicine
Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports
Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation: Two case reports